BPC-157

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PL 14736, Pliva, Croatia) and wound healing; presented at a symposium^[1]

This study investigated BPC-157's gastrointestinal cytoprotective and wound-healing properties across multiple rodent models of injury, including gastric ulcer, intestinal anastomosis, and tendon transection. The peptide was evaluated systemically and locally at microgram-per-kilogram concentrations. Key findings included accelerated mucosal healing, improved anastomotic strength, and concentration-dependent tendon repair in each respective model. The authors proposed that BPC-157 acts through a nitric oxide-dependent pathway and upregulation of growth factors including VEGF and EGF at injury sites.

Last verified: 2026-04-03

Accelerated healing of tendon injury by BPC-157 — effect on FAK-paxillin signaling pathway^[2]

Researchers used a rat Achilles tendon transection model to evaluate BPC-157's effect on the FAK-paxillin signaling pathway, which governs cell adhesion and migration at wound sites. Animals received BPC-157 intraperitoneally at 10 ug/kg for 14 days. Histological analysis demonstrated markedly improved collagen organization and increased tendon cross-sectional area compared to controls. Western blot analysis confirmed concentration-dependent upregulation of FAK and paxillin phosphorylation, providing mechanistic evidence for the observed accelerated healing.

Last verified: 2026-04-03